Adaptimmune Therapeutics (ADAP) Tops Q4 EPS by 21c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q4 EPS of ($0.03), $0.21 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $11.03 million versus the consensus estimate of $3.83 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Ennis (EBF) Reports In-Line Q1 EPS
• Nike names former Pfizer CFO David Denton as new finance chief